GH Research PLC

General Information

We are a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Our initial focus is on developing our novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Our portfolio currently includes GH001, our proprietary inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, our proprietary injectable 5-MeO-DMT product candidate. We have completed a Phase 1 healthy volunteer clinical trial, in which administration of GH001 via inhalation was observed to be well tolerated at the investigated single dose levels and in an individualized dosing regimen with intra-subject dose escalation within a single day. GH001 is currently being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. Based on observed clinical activity, we believe that administration of a single dose of GH001 has the potential to induce ultra-rapid remissions as measured by the Montgomery–Åsberg Depression Rating Scale, or MADRS, in certain patients. 

(Note: GH Research PLC upsized its IPO at pricing on  June 24, 2021,to 10 million shares – up from 8.33 million shares in the prospectus – at $16 – the top of its $14-to-$16 price range – to raise $160 million.)

Employees: 8
Founded: 2018
Contact Information
Address 28 Baggot Street Lower, Dublin 2, D02 NX43, Ireland
Phone Number + 353 1 437 8443
Web Address
View Prospectus: GH Research PLC
Financial Information
Market Cap $732.8mil
Revenues $0 mil (last 12 months)
Net Income $-1.6 mil (last 12 months)
IPO Profile
Symbol GHRS
Exchange NASDAQ
Shares (millions): 10.0
Price range $16.00 - $16.00
Est. $ Volume $160.0 mil
Manager / Joint Managers Cowen and Company/ Stifel
CO-Managers Canaccord Genuity/ JMP Securities
Expected To Trade: 6/25/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change